Finance

CytRx Corporation Regains Nasdaq Listing Compliance

November 20, 2017

LOS ANGELES, Nov. 17, 2017 /PRNewswire/ — CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it received written notification on November 16, 2017, from the NASDAQ Listing Qualifications Department that it has regained compliance with the minimum bid price requirement set forth in NASDAQ Listing Rule Section […]

NanoViricides Files Quarterly Report for Period Ending September 30, 2017

November 20, 2017

SHELTON, Conn., Nov. 20, 2017 /PRNewswire/ — NanoViricides, Inc. (NYSE MKT: NNVC) (the “Company”) a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the “Company”), filed its quarterly report for its first quarter of financial year 2018 in a timely manner with the Securities and Exchange Commission […]

Sage Therapeutics Announces Closing of $345 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares

November 20, 2017

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sage Therapeutics (Nasdaq: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 529,411 shares at the public […]

Brainsway Reports Record Quarterly Revenues in Third Quarter of 2017

November 20, 2017

HACKENSACK, N.J., Nov. 20, 2017 (GLOBE NEWSWIRE) — Brainsway Ltd. (TASE:BRIN), a leader in the advanced non-invasive treatment of brain disorders, today announced the Company’s financial results for the third quarter ended September 30, 2017. The Company’s revenues for the third quarter of 2017 increased by 27% over the revenues in the second quarter of […]

AmpliPhi Biosciences Reports Third Quarter 2017 Financial Results and Business Highlights Six patients with life-threatening S. aureus or P. aeruginosa infections treated to date with AB-SA01 or AB-PA01 under expanded access in the U.S. and Australia

November 15, 2017

SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced financial results for the third quarter ended September 30, 2017.   “I’m excited to report on the progress AmpliPhi made in the third quarter of 2017” Tweet this “I’m […]

Simulations Plus Reports FY2017 and Fourth Quarter FY2017 Financial Results

November 15, 2017

LANCASTER, Calif.–(BUSINESS WIRE)–Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of software for pharmaceutical discovery and development, today reported its financial results for its 2017 fiscal year (FY17) and fourth quarter (4Q17) ended August 31, 2017.   Results for the 2017 fiscal year (FY17):   Revenues were $24.1 million, up 20.9% over $20.0 million in […]

NovaBay Pharmaceuticals Reports Third Quarter 2017 Financial Results

November 15, 2017

EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for lid and lash hygiene in the domestic eye care market, reports financial results for the three and ninth months ended September 30, 2017 and provides a business update.   “This strategy is aimed at optimizing sales by effectively […]

GTx Provides Corporate Update and Reports Third Quarter 2017 Financial Results

November 15, 2017

MEMPHIS, Tenn.–(BUSINESS WIRE)–GTx, Inc. (Nasdaq:GTXI) today reported financial results for the third quarter of 2017 and highlighted recent accomplishments and upcoming milestones.   “Kegels in a Bottle: Preliminary Results of a Selective Androgen Receptor Modulator (GTx-024) for the Treatment of Stress Urinary Incontinence in Post-Menopausal Women” Tweet this “During the quarter, we achieved a key […]

Innovus Pharmaceuticals Reports Nine Month Net Revenue of $6.4 million and Net Loss Decrease of 51.6% Compared to the Same Period in 2016

November 15, 2017

SAN DIEGO–(BUSINESS WIRE)–Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB: INNV) today announced third quarter 2017 net revenue of $2.2 million compared to $1.9 million in net revenue for the same period in 2016. Net revenue for the nine months ended September 30, 2017 was $6.4 million compared to $3.1 million for the same […]

Ligand Provides Highlights from Today’s Analyst Day Event

November 15, 2017

SAN DIEGO–(BUSINESS WIRE)–At an Analyst Day event held today in New York City, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reviewed the recent progress of its business, including its revenue growth opportunities, its portfolio of partnered assets and its OmniAb® and Captisol® technology platforms. Management also discussed its Glucagon Receptor Antagonist internal development program, provided 2017 financial […]

Sage Therapeutics Prices Public Offering of Common Stock

November 15, 2017

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sage Therapeutics (Nasdaq: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 3,529,411 shares of its common stock at a public offering price of $85.00 per share. The gross proceeds to Sage Therapeutics from the offering, […]

Inozyme Pharma Raises $49 Million in a Series A Financing to Develop Therapies for Rare Diseases Affecting Soft Tissues and Bone

November 15, 2017

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Inozyme Pharma, Inc., a biotechnology company developing novel medicines to treat rare diseases of calcification, affecting soft tissues and bone, today announced it has raised a $49 million Series A financing. The financing was led by Longitude Capital, and included participation from New Enterprise Associates (NEA), Novo Ventures and Sanofi Ventures.   “With […]

Xenetic Biosciences Reports 2017 Third Quarter Financial Results and Provides Corporate Update

November 15, 2017

LEXINGTON, Mass.–(BUSINESS WIRE)–Xenetic Biosciences, Inc. (NASDAQ: XBIO) (“Xenetic” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced today its unaudited financial results for the quarter ended September 30, 2017.   Xenetic also provided a corporate update and anticipated milestones for […]

Immune Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides a Corporate Update

November 15, 2017

ENGLEWOOD CLIFFS, N.J.–(BUSINESS WIRE)–Immune Pharmaceuticals Inc. (NASDAQ:IMNP) (“Immune”) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced financial results for the quarter ending September 30, 2017 and provided a corporate update.   “We believe this financing will enable us to achieve several important milestones” Tweet this Third […]

Motif Bio secures up to US$20 million debt financing

November 15, 2017

NEW YORK, Nov. 15, 2017 (GLOBE NEWSWIRE) — Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the Company has entered into an agreement for up to US$20 million in debt financing with Hercules Capital, Inc. (NYSE:HTGC), a leader in customised debt financing for companies in […]

WPI Biochemist Receives $1.7 Million NIH Award to Develop New Molecular Methods for Synthetizing Treatments for Drug-Resistant Cancers

November 15, 2017

Worcester, Mass. – Nov. 15, 2017 – Anita Mattson, associate professor of chemistry and biochemistry at Worcester Polytechnic Institute (WPI), has received a $1.7 million award from the National Institutes of Health (NIH) to develop a new class of catalysts that could make it possible to reliably synthesize organic compounds that hold the promise of […]

Inozyme Pharma Raises $49 Million in a Series A Financing to Develop Therapies for Rare Diseases Affecting Soft Tissues and Bone

November 15, 2017

Cambridge, Mass., November 15, 2017 – Inozyme Pharma, Inc., a biotechnology company developing novel medicines to treat rare diseases of calcification, affecting soft tissues and bone, today announced it has raised a $49 million Series A financing. The financing was led by Longitude Capital, and included participation from New Enterprise Associates (NEA), Novo Ventures and […]

VBL Therapeutics Announces Third Quarter 2017 Financial Results

November 14, 2017

TEL AVIV, Israel, Nov. 14, 2017 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced financial results for the three and nine months ended September 30, 2017 and provided a corporate update. “We were pleased to announce last week the […]

ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update

November 14, 2017

Geneva, Switzerland and Boston, MA – November 14, 2017 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today reported financial results for the third quarter ended September 30, 2017 and provided a business update […]

Titan Pharmaceuticals Reports Third Quarter 2017 Financial Results

November 9, 2017

SOUTH SAN FRANCISCO, Calif., Nov. 9, 2017 /PRNewswire/ — Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery technology, today reported financial results for the third quarter 2017, and provided an update on its business.   Business highlights include:   Probuphine® […]

Aralez Announces Third Quarter 2017 Financial Results And Achieves Profitability on an Adjusted EBITDA Basis for the First Time in the Third Quarter

November 9, 2017

MISSISSAUGA, Ontario, Nov. 9, 2017 /PRNewswire/ — Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (“Aralez” or the “Company”) today announced financial results for the three and nine months ended September 30, 2017, and provided updated financial guidance for 2017 and its preliminary 2018 financial outlook. The Company also provided a business and corporate update. All […]

Concert Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Company Update

November 9, 2017

BUSINESS WIRE)– Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2017.   “This is an exciting time for our deuterium-based chemistry as we continue to demonstrate our technology’s ability to meaningfully improve the clinical properties of existing medicines. The CTP-656 program and subsequent asset purchase agreement with Vertex Pharmaceuticals […]

Aerie Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update

November 9, 2017

IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for the third quarter ended September 30, 2017, along with a general business update.   “Reconciliation of GAAP […]

AmpliPhi Biosciences to Hold 2017 Third Quarter and Business Update Conference Call on November 14

November 9, 2017

SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced that management will hold a business update conference call on Tuesday, November 14, 2017 beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).   Live Call:                                […]

Akebia Therapeutics Announces Third Quarter 2017 Financial Results

November 9, 2017

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced financial results for the third quarter ended September 30, 2017.   “Akebia continues to execute on our global Phase 3 program for vadadustat in collaboration with our […]

Zymeworks Reports Third Quarter 2017 Financial Results and Provides Business Update

November 9, 2017

VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, today reported financial results for the third quarter ended September 30, 2017.   $ZYME Reports Third Quarter 2017 Financial Results and Provides Business Update Tweet this “During the third quarter, we provided an […]

Aeterna Zentaris Reports Third Quarter 2017 Financial and Operating Results Prepares for Q4 2017 FDA Approval and Q1 2018 Commercial Launch

November 9, 2017

CHARLESTON, S.C.–(BUSINESS WIRE)–Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company engaged in developing and commercializing novel pharmaceutical therapies, today reported financial and operating results for the third quarter ended September 30, 2017.   “We are continuing our laser focus on preparation for the FDA approval of Macrilen™ by December 30, […]

Charles River Laboratories Announces Third-Quarter 2017 Results from Continuing Operations

November 9, 2017

WILMINGTON, Mass.–(BUSINESS WIRE)–Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2017. Revenue from continuing operations was $464.2 million, an increase of 9.0% from $425.7 million in the third quarter of 2016. Revenue growth was driven primarily by the Discovery and Safety Assessment and Manufacturing Support segments.   […]

ArQule Reports Third Quarter 2017 Financial Results Conference call scheduled today at 9:00 a.m. ET

November 9, 2017

BURLINGTON, Mass.–(BUSINESS WIRE)–ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the third quarter of 2017.   “Based on the preliminary results from the phase 1 NIH-sponsored Proteus syndrome trial, miransertib is the first drug to demonstrate activity and achieve clinical proof of concept in this indication” Tweet this For the quarter ended September […]

Concert Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Company Update

November 9, 2017

LEXINGTON, Mass.–(BUSINESS WIRE)–Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2017.   “This is an exciting time for our deuterium-based chemistry as we continue to demonstrate our technology’s ability to meaningfully improve the clinical properties of existing medicines. The CTP-656 program and subsequent asset purchase agreement with Vertex Pharmaceuticals […]

FEEDBACK